File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Biphasic emetic response of cyclophosphamide in the ferret

TitleBiphasic emetic response of cyclophosphamide in the ferret
Authors
KeywordsCyclophosphamide
Droperidol
Emesis
Ferret
Metaclopramide
Ondansetron
Issue Date1997
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/pharmbiochembeh
Citation
Pharmacology Biochemistry And Behavior, 1997, v. 58 n. 1, p. 179-182 How to Cite?
AbstractCyclophosphamide (177 mg/kg, IV; n = 8) produced it biphasic emetic response in the ferret with a mean ± SE of 23.3 + 4.0 emetic episodes during a 4-h observation period. The emetic profile of cyclophosphamide showed a first phase with 18.6 ± 3.9 episodes and a second phase with 4.7 ± 1.2 episodes. Ondansetron (0.07 and 0.13 mg/kg, IV) and droperidol (0.25 and 0.79 mg/kg, IV) significantly reduced the number of emetic episodes in the first phase. Metoclopramide (2.24, 4.08, and 7.07 mg/kg, IV) also significantly reduced the number of emetic episodes in the first phase, and the dose of 7.07 mg/kg completely prevented emetic episodes in the second phase. In addition, ondansetron-treated ferrets (0.04, 0.07, and 0.13 mg/kg, IV) had a significant increase in the number of emetic episodes in the second phase.
Persistent Identifierhttp://hdl.handle.net/10722/188531
ISSN
2020 Impact Factor: 3.533
2015 SCImago Journal Rankings: 1.121
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, RHen_US
dc.contributor.authorLao, Len_US
dc.contributor.authorBerman, BMen_US
dc.contributor.authorCarter, AKen_US
dc.contributor.authorWynn, RLen_US
dc.date.accessioned2013-09-03T04:10:08Z-
dc.date.available2013-09-03T04:10:08Z-
dc.date.issued1997en_US
dc.identifier.citationPharmacology Biochemistry And Behavior, 1997, v. 58 n. 1, p. 179-182en_US
dc.identifier.issn0091-3057en_US
dc.identifier.urihttp://hdl.handle.net/10722/188531-
dc.description.abstractCyclophosphamide (177 mg/kg, IV; n = 8) produced it biphasic emetic response in the ferret with a mean ± SE of 23.3 + 4.0 emetic episodes during a 4-h observation period. The emetic profile of cyclophosphamide showed a first phase with 18.6 ± 3.9 episodes and a second phase with 4.7 ± 1.2 episodes. Ondansetron (0.07 and 0.13 mg/kg, IV) and droperidol (0.25 and 0.79 mg/kg, IV) significantly reduced the number of emetic episodes in the first phase. Metoclopramide (2.24, 4.08, and 7.07 mg/kg, IV) also significantly reduced the number of emetic episodes in the first phase, and the dose of 7.07 mg/kg completely prevented emetic episodes in the second phase. In addition, ondansetron-treated ferrets (0.04, 0.07, and 0.13 mg/kg, IV) had a significant increase in the number of emetic episodes in the second phase.en_US
dc.languageengen_US
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/pharmbiochembehen_US
dc.relation.ispartofPharmacology Biochemistry and Behavioren_US
dc.subjectCyclophosphamide-
dc.subjectDroperidol-
dc.subjectEmesis-
dc.subjectFerret-
dc.subjectMetaclopramide-
dc.subjectOndansetron-
dc.subject.meshAnimalsen_US
dc.subject.meshAntiemetics - Pharmacologyen_US
dc.subject.meshAntineoplastic Agents, Alkylating - Administration & Dosage - Antagonists & Inhibitors - Pharmacologyen_US
dc.subject.meshCyclophosphamide - Administration & Dosage - Antagonists & Inhibitors - Pharmacologyen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshDroperidol - Pharmacologyen_US
dc.subject.meshFerrets - Physiologyen_US
dc.subject.meshInjections, Intravenousen_US
dc.subject.meshMaleen_US
dc.subject.meshMetoclopramide - Pharmacologyen_US
dc.subject.meshOndansetron - Pharmacologyen_US
dc.subject.meshVomiting - Chemically Induceden_US
dc.titleBiphasic emetic response of cyclophosphamide in the ferreten_US
dc.typeArticleen_US
dc.identifier.emailLao, L: lxlao1@hku.hken_US
dc.identifier.authorityLao, L=rp01784en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S0091-3057(97)00017-8en_US
dc.identifier.pmid9264088-
dc.identifier.scopuseid_2-s2.0-0030839424en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0030839424&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume58en_US
dc.identifier.issue1en_US
dc.identifier.spage179en_US
dc.identifier.epage182en_US
dc.identifier.isiWOS:A1997XP13500027-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridWong, RH=7402126848en_US
dc.identifier.scopusauthoridLao, L=7005681883en_US
dc.identifier.scopusauthoridBerman, BM=35458606800en_US
dc.identifier.scopusauthoridCarter, AK=16678419200en_US
dc.identifier.scopusauthoridWynn, RL=19537208500en_US
dc.identifier.issnl0091-3057-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats